A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability and Efficacy of FT-4101 in Overweight/Obese Subjects With NASH

This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent in overweight/obese subjects with NASH.

The study may be conducted in up to 2 dosing cohorts.

Study Overview

• Status: Terminated
• Conditions: Nonalcoholic Steatohepatitis (NASH); Overweight or Obesity
• Intervention / Treatment: Drug: FT-4101; Drug: FT-4101 placebo; Other: Deuterated Water

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Chula Vista, California, United States, 91911
      • ProSciento, Inc.
    • Montclair, California, United States, 91763
      • Catalina Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

• Meets all of the following criteria:

  1. CAP ≥ 300 dB/m by FibroScan® OR Liver biopsy within 24 months, consistent with NASH with stage 2-3 fibrosis
  2. Screening MRI-PDFF with ≥ 10% steatosis.
• Body mass index (BMI) > 25.0 to < 45.0 kg/m2
• Stable body weight

• Subjects with T2DM may also be included, if:

  1. Subject with T2DM is on stable doses of metformin monotherapy (subjects on combination therapy of metformin and sulfonylurea (SU) need to undergo washout period prior to dosing) with no changes in medication within the previous 6 months
  2. HbA1c < 9% (one retest is permitted with the result of the last test being conclusive)
  3. Fasting plasma glucose (FPG) < 240 mg/dL (<13.3 mmol/L)
• Waist circumference ≤ 57 inches
• Female subjects must be non-pregnant and non-lactating

Key Exclusion Criteria:

• Type 1 diabetes and type 2 diabetic subjects on insulin therapy
• Diabetic complications, such as acute proliferative retinopathy
• Recurrent severe hypoglycemia or hypoglycemic unawareness or recent severe ketoacidosis
• History of, or active, chronic liver disease due to alcohol, auto-immune, primary biliary cholangitis, HIV, HBV or active HCV-infection, Wilson's, α-1-antitrypsin deficiency, hemochromatosis, etc., and not due to NASH disease
• History of clinically significant or decompensated chronic liver disease including esophageal varices, ascites, encephalopathy or any hospitalization for treatment of chronic liver disease; or MELD score ≥ 10.
• History of significant cirrhosis of the liver
• Alcohol consumption greater than 14 drinks per week for men or greater than 7 drinks per week for women and/or positive alcohol breath test
• Introduction of an anti-obesity drug in the past 6 months prior to screening
• History of gastrointestinal malabsorptive bariatric surgery, any other gastrointestinal surgery that may induce malabsorption, history of bowel resection > 20 cm, any malabsorption disorder, severe gastroparesis, any GI procedure for weight loss, as well as clinically significant gastrointestinal disorders within less than 5 years
• Ingestion of drugs known to produce hepatic steatosis including corticosteroids, high- dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months
• History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease events, including congestive heart failure, unstable coronary artery disease, myocardial infarction
• Significant systemic or major illnesses other than liver disease, including cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the investigator, would preclude treatment with FT-4101 and/or adequate follow up
• History of chronic skin conditions such as psoriasis, eczema or any recurring rash/dermatitis requiring oral or topical corticosteroids or other topical applications within 12 months
• Hair loss or unexplained alopecia within 12 months
• History of chronic eye conditions, Sjögren syndrome or any history of dry eyes or allergic conjunctivitis requiring artificial tears or medicated eye drops or previous refractive surgery within 12 months (Subjects with dry eyes due to wearing contact lenses are eligible)
• History of major depression, anxiety, suicidal behavior or attempts, or other unstable psychiatric disorders (within 2 years of screening), requiring medical treatment
• Uncontrolled hypertension
• Any device or other contraindication with the MRI examination
• Ingestion of deuterated water within the previous 6 months
• Positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2) antibody
• Participation in any other clinical interventional study receiving active treatment within the previous 30 days or 5 half-lives, whichever is longer
• Unable to abstain from smoking during confinement periods
• History of illicit drug abuse
• Clinically under the effect of marijuana at screening
• Unwillingness to abstain from grapefruit (grapefruit containing food and beverages), star fruit (carambola), pomegranate, Seville orange and other food components that may interact with CYP3A4 from check-in throughout the entire course of the study
• Donation or loss of > 500 mL of blood or blood product within 56 days of dosing

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort B	Drug: FT-4101; FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.; Drug: FT-4101 placebo; FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.; Other: Deuterated Water; Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
Experimental: Cohort A	Drug: FT-4101; FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.; Drug: FT-4101 placebo; FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.; Other: Deuterated Water; Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment-emergent Adverse Events (TEAEs)	TEAEs were defined as an adverse events (AEs) with an onset that occurred after receiving the first dose of the study drug (AE start date greater than or equal to [>=] first dose date) and within 30 days after receiving the last dose of the study drug (AE start date - last dose date less than or equal to [<=] 30). Number of participants with TEAEs are reported.	From start of study drug administration up to 20 weeks
Number of Participants With Clinically Significant Changes in Laboratory Values	Number of participants with clinically significant changes in laboratory values (hematology, serum chemistry, and urinalysis) are reported.	Up to 20 weeks
Number of Participants With Clinically Significant Changes in Physical Examination	Number of participants with clinically significant changes in physical examination are reported.	Up to 20 weeks
Change From Baseline in Vital Signs: Blood Pressure (BP)	Change from baseline in blood pressure (systolic and diastolic) are reported.	Baseline, Day 92
Change From Baseline in Vital Signs: Heart Rate (HR)	Change from baseline in heart rate is reported.	Baseline, Day 92
Change From Baseline in Vital Signs: Respiratory Rate	Change from baseline in respiratory rate is reported.	Baseline, Day 92
Change From Baseline in Vital Signs: Temperature	Change from baseline in temperature is reported.	Baseline, Day 92
Change From Baseline in 12-lead Electrocardiogram (ECG) Parameters: ECG Mean Heart Rate	Change from baseline in ECG mean heart rate is reported.	Baseline, Day 92
Change From Baseline in 12-lead ECG Parameters: QT Interval	Change from baseline in QT interval is reported.	Baseline, Day 92
Change From Baseline in 12-lead ECG Parameters: PR Interval	Change from baseline in PR interval is reported.	Baseline, Day 92
Change From Baseline in 12-lead ECG Parameters: QRS Interval	Change from baseline in QRS interval is reported.	Baseline, Day 92
Change From Baseline in 12-lead ECG Parameters: RR Interval	Change from baseline in RR interval is reported.	Baseline, Day 92
Change From Baseline in 12-lead ECG Parameters: QTc (Corrected) Using the Fridericia Correction (QTcF) Interval	Change from baseline in QTcF interval is reported.	Baseline, Day 92
Percent Change From Baseline in Liver Fat on Magnetic Resonance Imaging- Proton Density Fat Fraction (MRI-PDFF)	Percent change from baseline in liver fat on MRI-PDFF is reported.	At week 12
Change From Baseline in Liver Fat on Magnetic Resonance Imaging- Proton Density Fat Fraction (MRI-PDFF)	Change from baseline in percentage of liver fat on MRI-PDFF is reported.	At week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Liver Fat on MRI-PDFF	Change from baseline in percentage of liver fat on MRI-PDFF is reported.	At week 6
Percent Change From Baseline in Liver Fat on MRI-PDFF	Percent change from baseline in liver fat on MRI-PDFF is reported.	At week 6
Percentage of Participants Experiencing a Relative Reduction of 30% or Greater of Liver Fat as Assessed by MRI-PDFF	Percentage of participants experiencing a relative reduction of 30% or greater of liver fat as assessed by MRI-PDFF at week 12 are reported.	At week 12
Change From Baseline in Alanine Aminotransferase (ALT)	Change from baseline in ALT is reported.	Baseline, Day 92
Change From Baseline in Aspartate Aminotransferase (AST)	Change from baseline in AST is reported.	Baseline, Day 92
Change From Baseline in Gamma-glutamyl Transferase (γGT)	Change from baseline in γGT is reported.	Baseline, Day 92
Change From Baseline in Alkaline Phosphatase	Change from baseline in alkaline phosphatase is reported.	Baseline, Day 92
Change From Baseline in Total Bilirubin	Change from baseline in total bilirubin is reported.	Baseline, Day 92
Maximum Plasma Concentration (Cmax) of FT-4101	Maximum plasma concentration (Cmax) of FT-4101 is reported	Cycle 1 (Day 1), Cycle 4 (Day 14); each Cycle length = 21 days
Area Under the Concentration-time Curve for a Dosing Interval (AUCtau) of FT-4101		Cycle 1 (Day 1), Cycle 4 (Day 14); each Cycle length = 21 days
Data for This Endpoint Was Not Collected and Analysed.		Cycle 1 (Day 1), Cycle 4 (Day 14); each Cycle length = 21 days

Other Outcome Measures

Outcome Measure	Time Frame
Assess the PD effect of FT-4101 on the inhibition of fasting hepatic de novo lipogenesis (DNL) after administration of multiple doses by using a 2-week deuterated water labeling protocol	Blood samples for PD analysis collected at up to 11 study visits over the course of approximately 20 weeks
Total sebum production	Skin surface sebum level measured using Sebumeter at up to 10 study visits over the course of approximately 20 weeks
Concentration of sebum lipids	Sebum lipids measured using Sebutape at up to 5 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - Enhanced liver fibrosis (ELF) score	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - Cytokeratin-18 fragments	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - FibroSure®	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - PRO-C3	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Fasting Lipids	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Gycemic parameters	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Adiponectin	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - FGF-21	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Malonyl carnitine	Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
Steatosis (CAP) determined by FibroScan®	Assessed at 12 weeks
Liver stiffness (LSM) determined by FibroScan®	Assessed at 12 weeks
Imaging parameters (Liver Volume [L], Liver Fat Volume Index [L]) assessed by MRI-PDFF	Imaging parameters assessed at up to 3 study visits over the course of approximately 20 weeks

Collaborators and Investigators

• Sponsor: Forma Therapeutics, Inc.
• Collaborators: ProSciento, Inc.
• Investigators: Study Director: Clinical Transparency (dept. 2834), MD, Novo Nordisk A/S

Study record dates

Study Major Dates

• Study Start (Actual): May 17, 2019
• Primary Completion (Actual): January 20, 2020
• Study Completion (Actual): January 20, 2020

Study Registration Dates

• First Submitted: June 10, 2019
• First Submitted That Met QC Criteria: June 27, 2019
• First Posted (Actual): July 2, 2019

Study Record Updates

• Last Update Posted (Estimated): October 20, 2025
• Last Update Submitted That Met QC Criteria: October 12, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Body Weight; Digestive System Diseases; Liver Diseases; Fatty Liver; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Obesity; Non-alcoholic Fatty Liver Disease
• Other Study ID Numbers: 4101-MET-201

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No